Verona Pharma plc (NASDAQ:VRNA – Get Free Report) CFO Mark W. Hahn sold 249,728 shares of the business’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $4.38, for a total value of $1,093,808.64. Following the transaction, the chief financial officer now directly owns 14,089,960 shares of the company’s stock, valued at $61,714,024.80. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Verona Pharma Stock Performance
Verona Pharma stock opened at $34.93 on Thursday. The firm has a fifty day simple moving average of $29.69 and a two-hundred day simple moving average of $21.26. The company has a quick ratio of 8.61, a current ratio of 8.61 and a debt-to-equity ratio of 0.72. Verona Pharma plc has a twelve month low of $11.39 and a twelve month high of $35.62. The company has a market capitalization of $2.79 billion, a PE ratio of -45.36 and a beta of 0.44.
Verona Pharma (NASDAQ:VRNA – Get Free Report) last released its earnings results on Thursday, August 8th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.53). During the same quarter in the prior year, the company earned ($0.11) earnings per share. Research analysts expect that Verona Pharma plc will post -2.07 EPS for the current year.
Institutional Trading of Verona Pharma
Analyst Upgrades and Downgrades
VRNA has been the subject of several research analyst reports. Truist Financial lifted their target price on shares of Verona Pharma from $38.00 to $44.00 and gave the company a “buy” rating in a research report on Wednesday, October 9th. Canaccord Genuity Group upped their target price on shares of Verona Pharma from $35.00 to $37.00 and gave the stock a “buy” rating in a research report on Monday, July 22nd. Wells Fargo & Company assumed coverage on Verona Pharma in a research note on Thursday, October 3rd. They issued an “overweight” rating and a $50.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target on shares of Verona Pharma in a research note on Tuesday, October 1st. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $39.33.
Read Our Latest Stock Analysis on Verona Pharma
Verona Pharma Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
Featured Articles
- Five stocks we like better than Verona Pharma
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- What is a Dividend King?
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.